

**PATIENT INFORMATION**  
**KISQALI® FEMARA® CO-PACK (kis kah' lee fe ma' ra koe' pak)**  
**(ribociclib tablets; letrozole tablets)**  
**co-packaged for oral use**

**What is the most important information I should know about KISQALI FEMARA CO-PACK?**

**KISQALI FEMARA CO-PACK may cause serious side effects, including:**

- **Lung problems.** KISQALI may cause severe or life-threatening inflammation of the lungs during treatment that may lead to death. Tell your healthcare provider right away if you have any new or worsening symptoms, including:
  - trouble breathing or shortness of breath
  - cough with or without mucus
  - chest pain
- **Heart rhythm problems (QT prolongation).** KISQALI FEMARA CO-PACK can cause a heart problem known as QT prolongation. This condition can cause an abnormal heartbeat and may lead to death. Your healthcare provider should check your heart and do blood tests before and during treatment with KISQALI FEMARA CO-PACK. Tell your healthcare provider right away if you have a change in your heartbeat (a fast or irregular heartbeat), or if you feel dizzy or faint.
- **Liver problems.** KISQALI FEMARA CO-PACK can cause serious liver problems. Your healthcare provider will do blood tests to check your liver before you start and while you take KISQALI FEMARA CO-PACK. Tell your healthcare provider right away if you get any of the following signs and symptoms of liver problems:
  - yellowing of your skin or the whites of your eyes (jaundice)
  - dark or brown (tea-colored) urine
  - feeling very tired
  - loss of appetite
  - pain on the upper right side of your stomach area (abdomen)
  - bleeding or bruising more easily than normal
- **Low white blood cell counts (neutropenia).** Low white blood cell counts are very common when taking KISQALI FEMARA CO-PACK and may result in infections that may be severe. Your healthcare provider should check your white blood cell counts before and during treatment with KISQALI FEMARA CO-PACK. Tell your healthcare provider right away if you have signs and symptoms of low white blood cell counts or infections, such as fever and chills.

Your healthcare provider may tell you to decrease your dose, temporarily stop or completely stop taking KISQALI if you develop certain serious side effects during treatment with KISQALI.

See **“What are the possible side effects of KISQALI FEMARA CO-PACK?”** for more information about side effects.

**What is KISQALI FEMARA CO-PACK?**

- KISQALI FEMARA CO-PACK is a prescription medicine used as the first hormonal based therapy to treat pre/perimenopausal or postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to other parts of the body (metastatic).
- KISQALI FEMARA CO-PACK contains 2 different types of medicines:
  - The violet tablet contains the medicine KISQALI (ribociclib).
  - The yellow tablet contains the medicine FEMARA (letrozole).

It is not known if KISQALI FEMARA CO-PACK is safe and effective in children.

**Do not take KISQALI FEMARA CO-PACK if you are allergic to letrozole or any of the ingredients of FEMARA.**

See the end of this Patient Information for a list of the ingredients in KISQALI FEMARA CO-PACK.

**Before you take KISQALI FEMARA CO-PACK, tell your healthcare provider about all your medical conditions, including if you:**

- have any heart problems, including heart failure, irregular heartbeats, and QT prolongation
- have ever had a heart attack
- have a slow heartbeat (bradycardia)
- have problems with the amount of potassium, calcium, phosphorus, or magnesium in your blood
- have fever, chills, or any other signs or symptoms of infection
- have liver problems
- are pregnant, or plan to become pregnant. KISQALI FEMARA CO-PACK can harm your unborn baby.
  - If you are able to become pregnant, your healthcare provider should do a pregnancy test before you start treatment with KISQALI FEMARA CO-PACK.
  - Females who are able to become pregnant and who take KISQALI FEMARA CO-PACK should use effective birth control during treatment and for at least 3 weeks after the last dose of KISQALI FEMARA CO-PACK.

- Talk to your healthcare provider about birth control methods that may be right for you during this time.
- If you become pregnant or think you are pregnant, tell your healthcare provider right away.
- are breastfeeding or plan to breastfeed. It is not known if KISQALI FEMARA CO-PACK passes into your breast milk. Do not breastfeed during treatment with KISQALI FEMARA CO-PACK and for at least 3 weeks after the last dose of KISQALI FEMARA CO-PACK.

**Tell your healthcare provider about all the medicines you take**, including prescription and over-the-counter medicines, vitamins, and herbal supplements. KISQALI FEMARA CO-PACK and other medicines may affect each other causing side effects. Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get a new medicine.

**How should I take KISQALI FEMARA CO-PACK?**

- Take KISQALI FEMARA CO-PACK exactly as your healthcare provider tells you.
- Do not change your dose or stop taking KISQALI FEMARA CO-PACK unless your healthcare provider tells you.
- KISQALI FEMARA CO-PACK comes in a carton that contains enough KISQALI tablets and FEMARA tablets for 28 days of treatment.
- Take KISQALI FEMARA CO-PACK each day at about the same time, preferably in the morning.
- You may take KISQALI FEMARA CO-PACK with food or without food.
- Swallow KISQALI tablets and FEMARA tablets whole. Do not chew, crush or split tablets before swallowing them.
- Do not take any KISQALI tablets and FEMARA tablets that are broken, cracked, or that look damaged.
- If you miss a dose or vomit after taking a dose of KISQALI FEMARA CO-PACK, do not take another dose on that day. Take your next dose at your regular time.
- If you take too much KISQALI FEMARA CO-PACK, call your healthcare provider right away or go to the nearest hospital emergency room.
- Inform your healthcare provider if you are pre- or peri-menopausal.

**What should I avoid while taking KISQALI FEMARA CO-PACK?**

- Avoid eating grapefruit and avoid drinking grapefruit juice during treatment with KISQALI FEMARA CO-PACK since these may increase the amount of KISQALI in your blood.

**What are the possible side effects of KISQALI FEMARA CO-PACK?**

**KISQALI FEMARA CO-PACK may cause serious side effects.**

- See "What is the most important information I should know about KISQALI FEMARA CO-PACK?"

**The most common side effects of KISQALI FEMARA CO-PACK include:**

- |               |                |                        |            |
|---------------|----------------|------------------------|------------|
| ● neutropenia | ● nausea       | ● infections           | ● fatigue  |
| ● leukopenia  | ● diarrhea     | ● hair loss (alopecia) | ● vomiting |
| ● headache    | ● constipation | ● back pain            | ● rash     |
| ● anemia      |                |                        |            |

KISQALI FEMARA CO-PACK may cause fertility problems in females and males, which may affect your ability to have children. Talk to your healthcare provider if you have concerns about fertility.

These are not all the possible side effects of KISQALI FEMARA CO-PACK.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

**How should I store KISQALI FEMARA CO-PACK?**

- Store KISQALI FEMARA CO-PACK at 68°F to 77°F (20°C to 25°C).
- Keep KISQALI FEMARA CO-PACK in its original container.

**Keep KISQALI FEMARA CO-PACK and all medicines out of the reach of children.**

**General information about the safe and effective use of KISQALI FEMARA CO-PACK.**

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use KISQALI FEMARA CO-PACK for a condition for which it was not prescribed. Do not give KISQALI FEMARA CO-PACK to other people, even if they have the same symptoms you have. It may harm them. You can ask your healthcare provider or pharmacist for more information about KISQALI FEMARA CO-PACK that is written for health professionals.

**What are the ingredients in KISQALI FEMARA CO-PACK?**

**KISQALI (ribociclib) tablets:**

**Active ingredient:** ribociclib

**Inactive ingredients:** colloidal silicon dioxide, crospovidone, hydroxypropylcellulose, magnesium stearate and microcrystalline cellulose. The film-coating contains iron oxide black, iron oxide red, lecithin (soya), polyvinyl alcohol (partially hydrolyzed), talc, titanium dioxide, and xanthan gum

**FEMARA (letrozole) tablets:**

**Active ingredient:** letrozole

**Inactive ingredients:** colloidal silicon dioxide, ferric oxide, hydroxypropyl methylcellulose, lactose monohydrate, magnesium stearate, maize starch, microcrystalline cellulose, polyethylene glycol, sodium starch glycolate, talc, and titanium dioxide

Distributed by: Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936

© Novartis

T2020-07

For more information, go to [www.KISQALI.COM](http://www.KISQALI.COM) or call 1-844-KISQALI (1-844-547-7254).

This Patient Information has been approved by the U.S. Food and Drug Administration.

Revised: January 2020